Business
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
DESMODA is the first and only FDA-approved desmopressin oral solutionCommercial launch expected on March 9thDESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing for patients of all agesThe product is expected to be a significant long-term growth contributor, with potential peak sales of $30-50 million annually and patent protection extending through 2044 DEER PARK, Ill., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Na
About this update from Eton Pharmaceuticals, Inc.
[{"type":"image","alt":"Eton Pharmaceuticals","displaySize":"","headline":null,"caption":"Eton Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/28f8553e49220b3671789b0841a3f340"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tNWDlhN7QWWIJSsJP_nqbA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/28f8553e49220b3671789b0841a3f340","width":300,"height":86}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"DESMODA is the first and only FDA-approved desmopressin oral solution","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"Commercial launch expected on March 9th","length":39,"tagName":"p"}]},{"val":[{"type":"text","content":"DESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing for patients of all ages","length":114,"tagName":"p"}]},{"val":[{"type":"text","content":"The product is expected to be a significant long-term growth contributor, with potential peak sales of $30-50 million annually and patent protection extending through 2044","length":171,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":393,"olType":false},{"type":"text","content":"DEER PARK, Ill., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S. Food and Drug Administration (FDA) approval of a New Drug Application (NDA) for DESMODA™ (desmopressin acetate) Oral Solution for the management of central diabetes insipidus, also known as arginine vasopressin deficiency (AVP-D), as antidiuretic replacement therapy for patients of all ages.","length":545,"tagName":"p"},{"type":"text","content":"DESMODA is the first and only FDA-approved oral liquid formulation of desmopressin, developed to support precise, individualized dosing in a disease where careful titration is essential to maintaining water balance. DESMODA is supplied as a ready-to-use oral solution (0.05 mg/mL) that does not require tablet splitting, crushing, refrigeration, mixing, or shaking.","length":365,"tagName":"p"},{"type":"text","content":"Eton estimates that there are more than 13,000 patients with central diabe...